Pharmaceutical - UCB

Filter

Current filters:

UCB

Popular Filters

1 to 25 of 59 results

UCB and Dermira link up for Cimzia in dermatology

UCB and Dermira link up for Cimzia in dermatology

03-07-2014

Belgium’s largest drugmaker UCB and Dermira, a privately held USA-based dermatology company, have entered…

CanadaCimziaDermatologicalsDermiraEuropeLicensingPharmaceuticalResearchUCBUSA

EIB and UCB partner to accelerate development of new medicines

EIB and UCB partner to accelerate development of new medicines

17-06-2014

The European Investment Bank (EIB), the financing institution of the European Union, has signed an agreement…

EuropeFinancialPharmaceuticalResearchUCB

UCB celebrates 10 years of investment in the UK since acquiring Celltech

UCB celebrates 10 years of investment in the UK since acquiring Celltech

02-06-2014

Belgian drugmaker UCB is today celebrating 10 years presence in the UK, following the company’s acquisition…

Business FinanceCelltechPharmaceuticalPharmaceutical sciencesUCBUK

UCB enters strategic alliance with Weill-Cornell in three discovery projects

03-04-2014

Belgian drugmaker UCB has launched a major, three-year strategic research alliance with Weill-Cornell…

MetabolicsPharmaceuticalRare diseasesResearchUCB

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019

13-03-2014

The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Sanofi and UCB in immune-mediated diseases research partnership

Sanofi and UCB in immune-mediated diseases research partnership

11-03-2014

French pharma major Sanofi and UCB, Belgium’s largest drugmaker, have entered into a scientific and…

Anti-Arthritics/RheumaticsGastro-intestinalsImmunologicalsPharmaceuticalResearchSanofiUCB

Core products boost UCB 2013 sales, but profits disappoint

26-02-2014

Belgium’s largest drugmaker UCB this morning reported financial results for 2013, with gross profit…

FinancialPharmaceuticalUCB

UCB CEO succession plan ahead of next wave of product launches

UCB CEO succession plan ahead of next wave of product launches

21-02-2014

Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch…

BoardroomManagementPharmaceuticalUCB

UCB links with UK’s MRC Technology for a fibrosis program

UCB links with UK’s MRC Technology for a fibrosis program

13-02-2014

Belgium’s leading drugmaker UCB and UK’s MRC Technology have entered an exclusive license agreement,…

LicensingPharmaceuticalResearchUCB

UCB and Biogen sign Asian license agreement for MS drugs

UCB and Biogen sign Asian license agreement for MS drugs

30-01-2014

Belgian drugmaker UCB and US biotech firm Biogen Idec have signed exclusive agreements granting UCB the…

AlprolixAsia-PacificBiogen IdecBiotechnologyEloctateLicensingNeurologicalPharmaceuticalTecfideraUCB

UCB launches online search for rare phenotypes

UCB launches online search for rare phenotypes

28-01-2014

Belgian drugmaker UCB (Euronext Brussels: UCB) has launched an online search to find rare phenotypes…

GeneticsGlobalPharmaceuticalRare diseasesResearchUCB

UCB’s Cimzia granted additional indication by US FDA

UCB’s Cimzia granted additional indication by US FDA

30-09-2013

UCB revealed today that the US Food and Drug Administration has approved its currently marketed drug…

Anti-Arthritics/RheumaticsCimziaNorth AmericaPharmaceuticalRegulationUCB

Vectura and UCB to collaborate on severe inflammatory disease

Vectura and UCB to collaborate on severe inflammatory disease

30-09-2013

Vectura and UCB have entered into a collaboration for the development of an innovative biologic immuno-modulatory…

BiotechnologyEuropeInflammatory diseasesPharmaceuticalResearchRespiratory and PulmonaryUCBVectura

Biotie completes planned portfolio review

Biotie completes planned portfolio review

24-09-2013

Biotie Therapies has revealed the outcome of its planned portfolio review, following its success earlier…

Biotie TherapiesLicensingLundbeckNeurelisNeurologicalNRL-1PharmaceuticalResearchSelincrotozadenantUCB

Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis

04-07-2013

Belgium's leading pharma company UCB (Euronext Brussels: UCB) said today (July 4) that it has granted…

Anti-Arthritics/RheumaticsLicensingolokizumabPharmaceuticalR-PharmaRoActemraRocheUCB

New study shows UCB's Neupro reduces NSBP in RLS patient

17-05-2013

Leading Belgian drugmaker UCB (Euronext Brussels: UCB) today (May 17) announced data from a double-blind,…

Cardio-vascularNeuproPharmaceuticalResearchUCB

Switch to anabolics driving osteoporosis market growth

11-03-2013

A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

1 to 25 of 59 results

Back to top